ecrin-mdr-crcClinical2021IPD Sharing (as of August 2023): No Description: Data will not be shared according to the Sponsor policy on data sharing. Taiho policy on data sharing may be found at https://www.taiho.co.jp/en/science/policy/clinical_trial_information_disclosure_policy/index.html.AdenocarcinomaAdvanced or Metastatic Solid TumorColorectal CancerNon-small Cell Lung CancerGastric CancerPancreatic Ductal AdenocarcinomaAdenocarcinomaColorectal CancerNon-small Cell Lung CancerGastric CancerAdvanced Or Metastatic Solid TumorPancreatic Ductal AdenocarcinomaInterventionalhttps://newmdr.ecrin.org/Study/2386215Japan6RamucirumabFutibatinibBevacizumabECRIN MDRRecruitingfalseAB122 Platform StudyThis is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.2021-06-152386215NCT04999761